A clinical trial involving cosyntropin has been updated to completed status as of July 28, 2026. The trial, registered as NCT00156767 and titled "Adrenal Function in Critical Illness," evaluated cosyntropin in the context of critically ill patients.
According to the registry update, the trial status is listed as COMPLETED. No phase was specified in the available record. The update does not include any posted results, outcomes, or efficacy data for cosyntropin in this trial.
This brief reflects only the status change recorded for this trial as of the given date. No conclusions about safety or effectiveness can be drawn from a completion status alone. Readers seeking further detail on the trial design or its eventual results should consult the official registry listing at clinicaltrials.gov under the identifier NCT00156767.
Cosyntropin remains an approved compound, and this update pertains specifically to the trial status noted above, not to any change in its regulatory standing. For additional context on cosyntropin, including its approved uses, readers can refer to the compound overview.